A

AbbVie

Global biopharmaceutical company developing medicines

TA Systems & Operations Specialist

Full-TimePosted on 10/20/2026
$65.5k - $125.5k/yr+ Short-term incentive program
Mid
Bachelor's
North Chicago, IL, USA
HybridOnsite required 3 days a week: Tuesday, Wednesday, and Thursday.
IT OperationsEnterprise Applications

About the job

Requirements
  • A bachelor's degree or equivalent combination of education and relevant experience.
  • At least 3 years of experience in business operations, systems analysis, reporting and analytics, human resources technology, process improvement, or related functions.
  • Experience generating reports, analyzing operational data, identifying trends, and developing business-focused recommendations.
  • Strong Microsoft Excel skills, including pivot tables, lookups, data manipulation, and trend analysis.
  • Experience working with enterprise systems, workflow platforms, or service-management technologies.
  • Experience documenting business requirements, workflows, and process improvements.
  • Strong analytical, critical-thinking, and problem-solving capabilities.
  • Proficiency in Microsoft PowerPoint and ability to develop clear presentations for business stakeholders.
  • Strong written and verbal communication skills, including explaining data findings and technical concepts to nontechnical audiences.
  • Ability to independently manage multiple priorities and assigned deliverables while collaborating with cross-functional stakeholders.
Responsibilities
  • Coordinate and support enhancements across Talent Acquisition technology platforms, including ServiceNow HRSD, SmartRecruiters, Workday, and related applications.
  • Gather, document, and translate business needs into functional requirements and user stories for HRIT and technology partners.
  • Maintain system enhancement requests and support backlog prioritization in partnership with Talent Acquisition Operations leadership.
  • Coordinate user acceptance testing, defect tracking, implementation readiness, and post-launch validation.
  • Identify opportunities to improve system functionality, user experience, workflow efficiency, and data accuracy.
  • Support system integrations by documenting business requirements, investigating operational issues, and coordinating resolution with technical teams.
  • Develop, generate, and maintain recurring and ad hoc operational reports using ServiceNow, Excel, and other available reporting tools.
  • Analyze ticket volumes, service-level performance, resolution trends, workflow effectiveness, system adoption, and operational performance.
  • Investigate recurring issues, process inefficiencies, and emerging trends to identify potential root causes.
  • Translate complex data into actionable business insights, identifying operational risks, improvement opportunities, and recommended actions.
  • Develop dashboards, visualizations, and executive-ready presentations that communicate performance results and their operational implications.
  • Summarize and present findings and recommendations to Talent Acquisition Operations, Operations & Innovation, and broader Talent Acquisition stakeholders.
  • Partner with Process Optimization and operational teams to evaluate improvement opportunities and measure outcomes.
  • Support workload forecasting, capacity analysis, and identification of emerging service-delivery trends.
  • Analyze existing Talent Acquisition workflows to identify manual activities, repetitive transactions, inefficiencies, and automation opportunities.
  • Review operational trends to identify opportunities for workflow redesign, self-service, automation, and process simplification.
  • Document current-state and future-state workflows, business rules, decision points, and functional requirements.
  • Partner with HRIT and Process Optimization to support automation design, implementation, testing, and validation.
  • Maintain a pipeline of identified workflow improvement and automation opportunities and provide recommendations on potential priorities.
  • Track and report the operational impact of implemented enhancements, including efficiency gains, reduced manual effort, and improved user experience.
  • Support the ongoing maintenance, organization, and optimization of the ServiceNow knowledge management environment.
  • Maintain knowledge content standards, article metadata, categorization, and documentation accuracy.
  • Analyze operational trends and recurring inquiries to identify knowledge gaps and opportunities to strengthen self-service capabilities.
  • Partner with subject matter experts to develop and update standard operating procedures, system documentation, and knowledge articles.
  • Support AI-enabled service-delivery initiatives, including Now Assist and virtual assistant capabilities, through knowledge optimization and identification of potential use cases.
  • Monitor knowledge effectiveness, adoption, and recurring support needs and recommend improvements to support operational efficiency and self-service.
  • Support the standardization of Talent Acquisition system workflows, documentation, business rules, and operational controls.
  • Coordinate with HRIT, HR Operations, Talent Acquisition leadership, and technology partners to support consistent system execution.
  • Maintain system process documentation, workflow inventories, enhancement records, and change logs.
  • Identify system-related risks, control gaps, and process inconsistencies and escalate issues or recommend corrective actions as appropriate.
  • Support technology releases, change readiness, stakeholder communications, and adoption activities.
  • Provide operational insights and recommendations to support Talent Acquisition technology planning and continuous-improvement priorities.
Desired Qualifications
  • Experience with ServiceNow HR Service Delivery, including reporting, workflows, knowledge management, or enhancement coordination.
  • Experience with HR or Talent Acquisition technologies such as SmartRecruiters, Workday, or similar platforms.
  • Experience with Power BI, Tableau, or comparable data-visualization tools.
  • Familiarity with automation, AI-enabled workflows, and digital-transformation initiatives.
  • Experience supporting user acceptance testing, system implementations, and technology enhancements.
  • Experience working in a global enterprise or shared-services environment.
  • Understanding of Talent Acquisition operations, recruiting processes, and HR service delivery.

About the company

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Apogee acquisition closed in 2026, expanding AbbVie’s immunology pipeline beyond Skyrizi and Rinvoq.
  • EU approvals for RINVOQ and EPKINLY in September 2026 broaden ex-U.S. revenue.
  • JUVMO launches in October 2026, adding a fresh neuroscience revenue line.

What critics are saying

  • Humira, Skyrizi, and Rinvoq concentration keeps AbbVie exposed if immunology growth slows in 2027.
  • Niaspan antitrust MDL and Biocell ALCL settlements carried $1.7 billion litigation accrual by June 2026.
  • Generic ubrogepant and atogepant suits threaten Ubrelvy and Qulipta exclusivity within years.

What makes AbbVie unique

  • Skyrizi and Rinvoq anchor AbbVie’s post-Humira immunology franchise across 11 EU RINVOQ indications.
  • JUVMO’s September 28, 2026 FDA approval gives AbbVie first-in-class Parkinson’s D1/D5 therapy.
  • AbbVie pairs blockbuster cash flows with Apogee, Iambic, and Valkai deal-making.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Remote Work Options
  • Flexible Work Hours
  • Professional Development Budget

Growth & Insights and Company News

6 month growth

4%

1 year growth

5%

2 year growth

5%
Yahoo Finance
Oct 22nd, 2026
Abbott stock: $247,767 in shares yields $500 a month in dividends ahead of Q3 earnings

Abbott Laboratories will report third-quarter earnings before the market opens on Wednesday, October 21. Analysts expect earnings of $1.41 per share, up from $1.30 a year earlier, and revenue of $12.99 billion, against $11.37 billion last year. On October 16, TD Cowen analyst Joshua Jennings reiterated a Buy rating and a $135 price target. Abbott pays a quarterly dividend of 63 cents per share ($2.52 a year), a yield of 2.42%. To earn $500 a month ($6,000 a year) from dividends alone, an investor would need about 2,381 shares, or roughly $247,767.

Yahoo Finance
Oct 21st, 2026
Retirees swap Social Security for 5 dividend stocks yielding up to 6.64%

Retirees looking for income beyond Social Security are turning to dividend stocks. The 2027 cost-of-living adjustment is tracking toward 3.3%, and five companies from different industries were screened for dividend safety first, then yield. Verizon yields 6.64% and Altria 6.17%. Verizon's free cash flow guidance of $21.94 billion to $22.14 billion covers its roughly $11.76 billion annual dividend. Altria's payout is about 79% of the low end of its 2026 earnings guidance. Realty Income pays monthly at a 5.99% yield and has raised its dividend 115 consecutive quarters. Enbridge yields 5.95%. AbbVie yields 2.48%, but its quarterly dividend has grown from $0.40 in 2013 to $1.73 in 2026. Risks include satellite competition for Verizon, falling cigarette volumes for Altria, and currency swings for Enbridge.

Yahoo Finance
Oct 19th, 2026
Merck and AbbVie shares jump 39% and 24% in 2026 as dividend picks for a decade

Healthcare stocks are rebounding in 2026, led by Merck and AbbVie. Merck shares have climbed 39% and AbbVie's 24%, against about 12% for the S&P 500. Merck's second-quarter revenue rose 5% to $16.6 billion, beating Wall Street estimates. Keytruda sales hit $8.4 billion, though the drug will likely lose patent exclusivity by 2028. A subcutaneous version, Keytruda Qlex, may help retain market share. Merck's forward dividend yield is 2.3%. AbbVie's revenue grew 10.2% to almost $17 billion, with adjusted earnings per share up 22.9% to $3.65. Skyrizi and Rinvoq sales each rose about 24%, and neither faces US competition until 2033 and 2037 respectively. AbbVie has raised its dividend for 54 straight years, including its time as part of Abbott Laboratories.

Yahoo Finance
Oct 19th, 2026
Buffett warns of a "gambling mood" in markets; Vertex, Eli Lilly and AbbVie built to weather a drop

Warren Buffett, now Berkshire Hathaway's chairman emeritus, gave his bluntest warning yet at the May shareholder meeting. "We've never had people in a more gambling mood than now," he told CNBC, pointing to individuals rushing into short-term options and betting on markets. He said this behaviour is risky for those taking part and may threaten the market, possibly leading to a drop. The article suggests drugmakers as defensive picks, since patients need treatments in any economy. Vertex Pharmaceuticals leads in cystic fibrosis treatment. Eli Lilly's tirzepatide drugs, Mounjaro and Zepbound, earned more than $14 billion of its $23 billion quarterly revenue. AbbVie's Rinvoq and Skyrizi each grew 24%, and it has raised its dividend for more than 50 consecutive years.

Yahoo Finance
Oct 18th, 2026
Ken Griffin's Citadel boosts AbbVie stake 546% in Q2 as defensive dividend play

Citadel founder and chief executive officer Ken Griffin made healthcare his biggest bet in the second quarter. He bought 2.7 million AbbVie shares, a 546% increase from the previous quarter, and added 6.7 million shares of Abbott Laboratories, up 349%. He also raised his Eli Lilly stake by 291%, the third-biggest individual equity add. The moves suggest a defensive stance. Healthcare stocks tend to hold up in downturns, and both AbbVie and Abbott are Dividend Kings, having raised dividends for 54 straight years. AbbVie yields 2.65% and trades at 16 times forward earnings. In the second quarter, its adjusted earnings rose 23% and net revenue rose 10%. Some 75% of analysts covering the stock rate it a buy.